A Phase 1 Study to Evaluate the Dose, Safety and Tolerability of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin) in Patients With Platinum Sensitive Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma With Peritoneal Carcinomatosis Following CRS
Latest Information Update: 09 Apr 2024
At a glance
- Drugs Radspherin (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; First in man
- Sponsors Oncoinvent
- 04 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 28 Sep 2023 According to Oncoinvent media release, interim safety data from this study will be presented at the 24th Congress of the European Society of Gynaecological Oncology (ESGO)
- 28 Sep 2023 Interim safety data from this study published in the Oncoinvent Media Release